Huaren Pharmaceutical participates in the Beijing-Tianjin-Hebei "3+N" alliance for the selected procurement of certain Western medicines and traditional Chinese medicines through volume-based procurement
Huaren Pharmaceutical and its wholly-owned subsidiary participated in the "3+N" alliance for the procurement of Western medicine and traditional Chinese medicine in the Beijing-Tianjin-Hebei region, and were selected for multiple products. According to the announcement from the Tianjin Pharmaceutical Procurement Center, the expected sales revenue for the selected products in 2024 is RMB 13.0389 million, accounting for 0.96% of the company's operating revenue in 2024. Among them, the sales revenue of mixed sugar electrolyte injection, betamethasone sodium phosphate injection, and hydroxyethyl starch 130/0.4 sodium chloride injection accounts for 0.06%, 0.16%, and 0.74%, respectively
According to the announcement from Huaren Pharmaceutical (300110.SZ), the company and its wholly-owned subsidiaries, Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huaren Pharmaceutical (Rizhao) Co., Ltd., have recently actively participated in the bidding for the "3+N" alliance of Western medicine and traditional Chinese medicine volume-based linkage procurement (Project No.: LH-YD2025-1) in the Beijing-Tianjin-Hebei region. According to the results announced by the Tianjin Medical Procurement Center, the products of the company and its wholly-owned subsidiaries, including mixed sugar electrolyte injection, betamethasone sodium phosphate injection, and hydroxyethyl starch 130/0.4 sodium chloride injection, have been selected for this volume-based linkage procurement.
The total sales revenue of the selected products for 2024 is expected to be 13.0389 million yuan, accounting for 0.96% of the company's total operating revenue for 2024. Among them, the sales revenue of mixed sugar electrolyte injection for 2024 is 823,200 yuan, accounting for 0.06% of the company's total operating revenue for 2024; the sales revenue of betamethasone sodium phosphate injection for 2024 is 2.2203 million yuan, accounting for 0.16% of the company's total operating revenue for 2024; and the sales revenue of hydroxyethyl starch 130/0.4 sodium chloride injection is 9.9954 million yuan, accounting for 0.74% of the company's total operating revenue for 2024
